Phase
Condition
Anemia
Hemoglobinuria, Paroxysmal
Proteinuria
Treatment
Ravulizumab
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Adult (aged ≥18) patients with PNH receiving ravulizumab treatment in the frames ofNDP in Poland.
Patients willing to participate in the study and signed ICF.
Exclusion
Exclusion Criteria:
Those who participated in ravulizumab clinical trial in the past, and/or those whoparticipated/plans to participate in clinical trial on/after the date of firstravulizumab infusion through NDP.
Cognitive incapacity, unwillingness or language barriers precluding adequateunderstanding or cooperation.
Study Design
Study Description
Connect with a study center
Research Site
Bialystok,
PolandSite Not Available
Research Site
Brzozow,
PolandActive - Recruiting
Research Site
Bydgoszcz,
PolandActive - Recruiting
Research Site
Gdansk,
PolandActive - Recruiting
Research Site
Katowice,
PolandSite Not Available
Research Site
Krakow,
PolandActive - Recruiting
Research Site
Lodz,
PolandActive - Recruiting
Research Site
Lublin,
PolandActive - Recruiting
Research Site
Opole,
PolandActive - Recruiting
Research Site
Szczecin,
PolandActive - Recruiting
Research Site
Walbrzych,
PolandActive - Recruiting
Research Site
Warsaw,
PolandSite Not Available
Research Site
Wroclaw,
PolandActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.